Australia markets closed

Living Cell Technologies Limited (LCT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.01400.0000 (0.00%)
At close: 03:43PM AEST

Living Cell Technologies Limited

Rialto South Tower
Level 23 525 Collins Street 201 Sussex Street
Melbourne, VIC 3000
61 3 8689 9997

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. David Richard HainsworthCEO & Exec. Chairman40kN/A1973
Mr. Daya UkaChief Financial Officer153.08kN/AN/A
Dr. Belinda Di BartoloChief Operations Officer182.33kN/AN/A
Dr. Carolyn M. Sue A.M., B.S., Ph.D.Member of Medical Advisory Board & Chief Medical Officer of NTCELL50kN/A1963
Mr. Madhukar Bhalla FCISCompany Sec.40kN/A1959
Dr. James A. MckennaChief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.

Corporate governance

Living Cell Technologies Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.